Denna sida på svenska
Loading profile information...

About me

Bachelor’s Degree in Biology and PhD in Molecular Biology from Universidad Autónoma de Madrid. His research career started in Colombia, working with animal models related to malaria vaccine development. He went on to obtain his PhD in the Centro de Biología Molecular “Severo Ochoa” in Madrid, with a focus on the development of new strategies for allergen-specific immunotherapy. After a first postdoctoral stage in a pharmaceutical company, where he worked on new vaccine adjuvants, he moved to Sweden, to join the Cancer immune and Gene Therapy Lab in Karolinska Institute. His current line of research is focused on new immunotherapies for malignant melanoma.

He is currently a member of the board of the ACES-SFFS, the Spanish Researchers Associacion in Sweden



Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
Ligtenberg Ma, Pico De Coaña Y, Shmushkovich T, Yoshimoto Y, Truxova I, Yang Y, et al
Molecular therapy : the journal of the American Society of Gene Therapy 2018;26(6):1482-1493

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
Tallerico R, Cristiani Cm, Staaf E, Garofalo C, Sottile R, Capone M, et al
Oncoimmunology 2017;6(2):e1261242-

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
De Coana Yp, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nystrom M, et al
ONCOTARGET 2017;8(13):21539-21553

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
Pico De Coaña Y, Choudhury A, Kiessling R
Trends in molecular medicine 2015;21(8):482-91

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
Pico De Coaña Y, Masucci G, Hansson J, Kiessling R
Cancer immunology, immunotherapy : CII 2014;63(9):977-83

Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells
Kiessling R, Mao Y, Pico De Coaña Y
Clinical cancer research : an official journal of the American Association for Cancer Research 2014;20(6):1401-3

Analysis of calcium-induced conformational changes in calcium-binding allergens and quantitative determination of their IgE binding properties
Parody N, Fuertes Ma, Alonso C, Pico De Coaña Y
Methods in molecular biology (Clifton, N.J.) 2013;963():115-25

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production
Pico De Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, et al
Cancer immunology research 2013;1(3):158-62

Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)
Coana Yp, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, et al

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms
Mao Y, Poschke I, Wennerberg E, Pico De Coaña Y, Egyhazi Brage S, Schultz I, et al
Cancer research 2013;73(13):3877-87

Modulation of the Humoral Response to Dermatophagoides pteronyssinus Allergens in BALB/c Mice by Extract Modification and Adjuvant Use
De Coana Yp, Carnes J, Gallego Mt, Alonso C, Parody N

A Modified Protocol for RNA Isolation from High Polysaccharide Containing Cupressus arizonica Pollen. Applications for RT-PCR and Phage Display Library Construction
Pico De Coana Y, Parody N, Fernandez-caldas E, Alonso C

Molecular cloning and characterization of Cup a 4, a new allergen from Cupressus arizonica
Pico De Coana Y, Parody N, Fuertes Ma, Carnes J, Roncarolo D, Ariano R, et al

Quantifying Aotus monkey cytokines by real-time quantitative RT-PCR
Pico De Coana Y, Barrero C, Cajiao I, Mosquera C, Patarroyo Me, Patarroyo Ma
CYTOKINE 2004;27(4-5):129-33

A highly infective Plasmodium vivax strain adapted to Aotus monkeys: Quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development
Pico De Coana Y, Rodriguez J, Guerrero E, Barrero C, Rodriguez R, Mendoza M, et al
VACCINE 2003;21(25-26):3930-7

Show all publications